Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
Abstract Cancer immunotherapy, especially immune checkpoint therapy, has revolutionized therapeutic options by reactivating the host immune system. However, the efficacy varies, and only a small portion of patients develop sustained antitumor responses. Hence, illustrating novel strategies that impr...
Main Authors: | Xianyong Zhou, Chen Li, Tong Chen, Wenhao Li, Xiaolong Wang, Qifeng Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-02-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12943-023-01746-6 |
Similar Items
-
The roles of RNA N6-methyladenosine in esophageal cancer
by: Chuan Teng, et al.
Published: (2022-11-01) -
Regulatory role of RNA N6-methyladenosine modifications during skeletal muscle development
by: Baojun Yu, et al.
Published: (2022-08-01) -
Roles and implications of mRNA N6‐methyladenosine in cancer
by: Lingxing Zeng, et al.
Published: (2023-07-01) -
Targeting the RNA m6A modification for cancer immunotherapy
by: Xinxin Li, et al.
Published: (2022-03-01) -
Functions of RNA N6-methyladenosine modification in acute myeloid leukemia
by: Xue Zheng, et al.
Published: (2021-05-01)